Drug Development Updates

Stay informed with timely notifications on clinical trials and research advancements.

Garadacimab

Generic Name: Garadacimab

Drug Type: Biotech

CAS Number: 2162134-62-3

Unique Ingredient Identifier: 32W6AJL0DY

Overview

Garadacimab is under investigation in clinical trial NCT04281524 (A Clinical Study to Test the Efficacy and Safety of CSL312 on Catheter-associated Blood Clot Formation in Subjects With Cancer Who Receive Chemotherapy Through a PICC Line).

Background

Indication

No indication information available.

Associated Conditions

No associated conditions information available.

Clinical Trials

Safety Study in Subjects ≥ 12 Years of Age With Hereditary Angioedema Switching to Garadacimab

Phase 4

Recruiting

Posted: 2025/02/04

Sponsor:CSL Behring

ID:NCT06806657

CSL312_3003 Safety and Pharmacokinetic Study in Subjects 2 to 11 Years of Age With Hereditary Angioedema

Phase 3

Active, not recruiting

Posted: 2023/04/19

Sponsor:CSL Behring

ID:NCT05819775

A Study to Compare the Pharmacokinetics of CSL312 Administered by Prefilled Syringe Assembled to Autoinjector to the Pharmacokinetics Administered by Prefilled Syringe Assembled to Needle Safety Device in Healthy Subjects

Phase 1

Completed

Posted: 2022/04/01

Sponsor:CSL Behring

ID:NCT05306275

Garadacimab Safety, Pharmacokinetics, and Pharmacodynamics in Idiopathic Pulmonary Fibrosis

Phase 2

Completed

Posted: 2021/11/23

Sponsor:CSL Behring

ID:NCT05130970

Long-term Safety and Efficacy of CSL312 (Garadacimab) in the Prophylactic Treatment of Hereditary Angioedema Attacks

Phase 3

Active, not recruiting

Posted: 2021/02/04

Sponsor:CSL Behring

ID:NCT04739059

FDA Approved Products

No FDA products found for this drug

Singapore Approved Products

No Singapore products found for this drug

Related News

Major Advances in Angioedema Pipeline: Intellia's Gene Therapy Enters Phase 3 as Multiple Companies Race for Novel Treatments

3 months ago

Intellia Therapeutics has initiated Phase 3 trials for NTLA-2002, a groundbreaking CRISPR-based gene therapy for hereditary angioedema, with potential U.S. launch targeted for 2027.

CSL's Breakthrough: New Monthly Injectable Andembry Approved for Hereditary Angioedema

4 months ago

Australian regulators have approved Andembry, a novel engineered antibody treatment developed by CSL in Melbourne, offering new hope for hereditary angioedema patients.

Phase 3 Trial Success Paves Way for CSL's Rare Disease Drug Filing

5 months ago

CSL's phase 3 trial of garadacimab, a monthly therapy for hereditary angioedema (HAE), shows promising results, positioning it as a strong competitor to Takeda's Takhzyro. The study highlights garadacimab's efficacy and convenience, with significant reductions in monthly attacks and a favorable safety profile.

Major Breakthroughs in HAE Treatment: 2024 Highlights Gene Editing and Novel Therapeutics

5 months ago

2024 marked significant advances in hereditary angioedema (HAE) treatment, with Intellia's gene-editing therapy NTLA-2002 showing a remarkable 95% reduction in monthly attacks. The year also saw important developments in multiple therapeutic candidates, including donidalorsen and garadacimab, while established treatments like Takhzyro demonstrated continued efficacy in adolescent populations.

CSL's Andembry (Garadacimab) Approved in Europe and UK for Hereditary Angioedema

5 months ago

The European Commission and the MHRA have approved CSL's Andembry (garadacimab) for preventing hereditary angioedema (HAE) attacks in patients aged 12 and older.

Drug Development Updates

Stay informed with timely notifications on clinical trials and research advancements.

Home Terms & Conditions Privacy Policy